Prothena Q1 net income $32.7M on $50M milestone; raises cash guidance

PROTHENA CORP PUBLIC LTD CO

2026-Q1 EPS reported $0.60 revenue$51,084,000

Net income of $32.7M ($0.60 diluted EPS) vs net loss of $60.2M ($1.12 loss) in Q1 2025.
Revenue $51.1M (vs $2.8M), primarily from $50M Novo Nordisk milestone for coramitug Phase 3 enrollment.
Updated FY2026 net cash used guidance to $18-23M (prior $50-55M); year-end cash ~$273M (midpoint), up $18M.
Initiated up to $100M share repurchase program; repurchased 788,990 shares for $7.3M through Q1.
PRX019 Phase 1 completed; potential $55M milestone if Bristol Myers Squibb advances by YE 2026.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.